Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer

被引:173
|
作者
Srokowski, Tomasz P. [1 ]
Fang, Shenying [1 ]
Hortobagyi, Gabriel N. [1 ]
Giordano, Sharon H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
COMORBIDITY; SURVIVAL; INDEX; WOMEN;
D O I
10.1200/JCO.2008.17.5935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate whether diabetes affects patterns of adjuvant chemotherapy use, toxic effects of chemotherapy, and breast cancer outcomes. Patients and Methods By using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients aged 66 years or older who had stages I through III breast cancer that was diagnosed between 1992 and 2002. Multivariable regression analyses were performed to determine the effect of diabetes on use of chemotherapy, toxicities, and outcomes. The risks of all-cause mortality and breast cancer specific (BCS) mortality were estimated with the Kaplan-Meier method. Results Our cohort had 70,781 men and women, of whom 14,414 (20.36%) had diabetes. Among people who received chemotherapy (n = 11,826), 21.0% were diabetics. In this group, diabetics had lower odds of receiving anthracyclines (odds ratio [OR], 0.78; 95% CI, 0.71 to 0.87) and taxanes (OR, 0.86; 95% CI, 0.75 to 0.99). Diabetes was associated with increased odds of being hospitalized for any chemotherapy toxicity (OR, 1.38; 95% CI, 1.23 to 1.56), for infection or fever (OR, 1.43; 95% CI, 1.2 to 1.7), for neutropenia (OR, 1.22; 95% CI, 1.03 to 1.45), for anemia (OR, 1.24; 95% CI, 1.05 to 1.47), and for any cause (OR, 1.32; 95% CI, 1.19 to 1.46). Patients with diabetes had higher all-cause mortality (hazard ratio [HR], 1.35; 95% CI, 1.31 to 1.39). There was a significant interaction between diabetes and chemotherapy use for BCS mortality. Diabetic and nondiabetic patients who did not receive chemotherapy had similar BCS mortality, but diabetic patients who did receive chemotherapy had higher BCS mortality than nondiabetic patients (OR, 1.20; 95% CI, 1.07 to 1.35). Conclusion In this observational, hypothesis-generating study, patients who have breast cancer and diabetes are at increased risk of chemotherapy-related toxicities compared with nondiabetic patients who are receiving chemotherapy and have higher all-cause mortality.
引用
收藏
页码:2170 / 2176
页数:7
相关论文
共 50 条
  • [1] Impact of diabetes mellitus on complications of chemotherapy and outcomes in older patients with breast cancer
    Srokowski, T. P.
    Fang, S.
    Hortobagyi, G. N.
    Giordano, S. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Impact of Comorbid Diabetes Mellitus on Adjuvant Chemotherapy Selection in Older Rectal Cancer Patients
    Htoo, Phyo T.
    Sanoff, Hanna K.
    Lund, Jennifer L.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 79 - 79
  • [3] Adjuvant chemotherapy in older patients with breast cancer
    Agnes Jager
    Jaap Verweij
    Stefan Sleijfer
    [J]. Nature Reviews Clinical Oncology, 2009, 6 : 563 - 565
  • [4] Adjuvant chemotherapy in older patients with breast cancer
    Jager, Agnes
    Verweij, Jaap
    Sleijfer, Stefan
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (10) : 563 - 565
  • [5] Impact of adjuvant chemotherapy on clinical and biological ageing in older breast cancer patients
    Brouwers, Barbara
    Hatse, Sigrid
    Dal Lago, Lissandra
    Neven, Patrick
    Vuylsteke, Peter
    Debrock, Guy
    Van den Bulck, Heidi
    Smeets, Ann
    Bechter, Oliver
    Swerts, Evalien
    Bailur, Jithendra Kini
    Kenis, Cindy
    Laenen, Annouschka
    Dalmasso, Bruna
    Schoffski, Patrick
    Pawelec, Graham
    Wildiers, Hans
    [J]. CANCER RESEARCH, 2015, 75
  • [6] Use and outcomes of adjuvant chemotherapy in older women with breast cancer
    Giordano, Sharon H.
    Duan, Zhigang
    Kuo, Yong-Fang
    Hortobagyi, Gabriel N.
    Goodwin, James S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2750 - 2756
  • [7] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Midori Morita
    Akihiko Shimomura
    Emi Tokuda
    Yoshiya Horimoto
    Yukino Kawamura
    Yumiko Ishizuka
    Katsutoshi Sekine
    Sayaka Obayashi
    Yuki Kojima
    Yukari Uemura
    Toru Higuchi
    [J]. Breast Cancer, 2022, 29 : 498 - 506
  • [8] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Morita, Midori
    Shimomura, Akihiko
    Tokuda, Emi
    Horimoto, Yoshiya
    Kawamura, Yukino
    Ishizuka, Yumiko
    Sekine, Katsutoshi
    Obayashi, Sayaka
    Kojima, Yuki
    Uemura, Yukari
    Higuchi, Toru
    [J]. BREAST CANCER, 2022, 29 (03) : 498 - 506
  • [9] Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients
    Gao, Ying
    Hao, Jie
    Zhang, Zhendong
    [J]. CLINICAL INTERVENTIONS IN AGING, 2024, 19 : 1281 - 1286
  • [10] The impact of postoperative complications and delay of adjuvant chemotherapy on oncological outcomes in patients with colorectal cancer
    Fransgaard, Tina
    Caspar Thygesen, Lau
    Gogenur, Ismail
    [J]. COLORECTAL DISEASE, 2021, 23 (05) : 1132 - 1140